Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

DefiniGen Ltd.. (10/30/18). "Press Release: DefiniGen Licenses Broad Institute CRISPR-Cas9 Gene Editing Technology for Optimized Metabolic Disease Drug Development". Cambridge.

Organisations Organisation DefiniGen Ltd.
  Organisation 2 Broad Institute (MIT / Harvard)
  Group MIT (Massachusetts Institute of Technology)
Products Product CRISPR gene editing technology
  Product 2 cell line development (research assays)
Index term Index term DefiniGen–MIT: CRISPR technology, 201810– commercial license to CRISPR-Cas9 gene editing technology from Broad Institute
Person Person Yeo, Marcus (Definigen Ltd 201406 CEO)
     


DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Broad Institute CRISPR-Cas9 technology will be combined with DefiniGEN’s best-in-class induced Pluripotent Stem Cell (iPSC) differentiation platform to generate preclinical cell models which can accelerate Type 2 diabetes, non-alcoholic steatohepatitis (NASH), and orphan liver disease drug discovery programmes.

“Through our license with Broad Institute, we are pleased to be able to enhance our customer’s research programs by offering state-of-the-art CRISPR-Cas9 gene edited disease model cell products and custom services” commented Dr Marcus Yeo CEO of DefiniGEN.

DefiniGEN will produce CRISPR-Cas9 gene edited cells, enabling customers to exploit the power of genome editing, alongside world-leading stem cell production and disease modelling capabilities.

   
Record changed: 2018-11-03

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for DefiniGen Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top